Cannabis Law and Access in Poland

Poland's cannabis law: what the framework actually says

Forty-three EU member states, four different scheduling regimes, and somehow every conversation still starts with "is it legal there?" I spent part of last winter cross-referencing the Polish Act on Counteracting Drug Addiction against the European Monitoring Centre for Drugs and Drug Addiction's country profiles, and the short version is: Poland is a more instructive case than most people realise. Not because the law is dramatic, but because it sits in an interesting middle position , a functional medical access pathway running alongside one of the stricter recreational-use frameworks in Central Europe.

Worth saying upfront: this is not Australian law. Australian readers should understand that accessing cannabis in any form here is governed by the TGA, the Poisons Standard, and pathways like the Special Access Scheme and the Authorised Prescriber scheme. The Polish framework described below has no bearing on what is lawful in Australia.

The legal foundation: Act on Counteracting Drug Addiction

Poland's primary drug law is the Ustawa o przeciwdziałaniu narkomanii , the Act on Counteracting Drug Addiction , originally passed in 2005 and amended several times since. Cannabis is classified as a Group I-P substance under that Act, which is the most restrictive classification for psychoactive substances. Recreational possession, cultivation, and supply remain criminal offences.

The 2011 amendment introduced a minor-possession provision: prosecutors may (not must) discontinue proceedings where a person is found in possession of a small quantity intended solely for personal use. "Small quantity" is not defined in the statute itself; discretion falls to prosecutors and courts, which creates real inconsistency in practice. That's not a minor quirk; it means outcomes vary significantly by region and individual prosecutor. I'd argue this is the single biggest structural weakness in the Polish framework, because discretionary decriminalisation without a defined threshold produces outcomes that look arbitrary from the outside.

The 2017 medical cannabis amendment

A significant amendment in 2017 legalised medicinal cannabis products, specifically cannabis-based pharmaceutical preparations. The change added provisions allowing import and dispensing of standardised cannabis products, meaning flower, oil extracts, and other preparations that have passed quality controls, through the Polish pharmaceutical system.

Products must meet quality standards consistent with Good Manufacturing Practice. If you want to understand why GMP matters to consistency of preparations containing compounds like tetrahydrocannabinol and cannabidiol, our GMP glossary entry covers it. The short answer is that without standardisation you cannot reliably characterise what is in a product, and that matters enormously to any regulatory framework built on scheduled substances.

Under the 2017 provisions, a physician registered in Poland can issue a prescription for a cannabis preparation. The prescription is filled at a pharmacy, which must hold an import licence. Domestic cultivation for medicinal product manufacture was subsequently permitted in stages, though the practical infrastructure for large-scale domestic production has been slow to develop.

What can actually be prescribed

Polish regulations permit the prescription of whole cannabis flower and standardised extracts, including preparations with varying ratios of THC to CBD. There is no fixed list of qualifying conditions written into the primary statute; the framework is written as physician discretion within the normal scope of medical practice, rather than a condition-gated system like some other EU countries use.

That said, reimbursement is a separate matter entirely. As of the time of writing, cannabis preparations are not covered by the National Health Fund (NFZ), which means patients pay out of pocket. This has been a persistent point of criticism from Polish patient advocacy groups. Access exists on paper; cost is the practical barrier.

The compounds present in a prescribed preparation depend entirely on what is actually in the product. A full-spectrum preparation will contain a range of cannabinoids alongside terpenes and other plant constituents, whereas a more refined extract might approach a broad-spectrum or even isolate profile. Polish regulations do not mandate one over another; the composition is a product characteristic declared by the manufacturer.

CBD's distinct position

Here things get somewhat complicated, as they do across most of Europe. CBD derived from industrial hemp (Cannabis sativa L. with THC content below 0.2% at the time of EU harmonisation) has occupied a contested regulatory space. Poland, in line with EU novel food rules following the 2019 European Court of Justice Kanavape judgment, treats CBD extracts intended for oral consumption as novel foods subject to the European Food Safety Authority authorisation process.

So: a pharmacist-dispensed CBD-containing medicine prescribed by a physician sits within the medical cannabis framework. A CBD oil sold in a wellness shop is subject to novel food regulations. The two pathways are legally distinct, even though both products may contain the same compound. I find this genuinely interesting from a regulatory architecture perspective, it reflects the awkward EU reality of cannabis policy developed across multiple directorates simultaneously.

Recreational use: still a criminal matter

This is unambiguous. Growing, supplying, and possessing cannabis for non-medical purposes remains a criminal offence under Polish law. Penalties under the Act on Counteracting Drug Addiction include fines and imprisonment; supply and trafficking carry substantially higher maximum penalties than possession. The prosecutorial discretion on small personal-use quantities I described earlier is not decriminalisation in any formal sense, it is discretion, and it can go either way.

I was reading a Euronews analysis of EU drug law variation over a bowl of soup at my desk in Canberra last month, cross-checking it against the EMCDDA country drug reports. The variation across EU member states is genuinely striking; you have Portugal's 2001 decriminalisation model at one end and Poland's approach at the other, both operating inside the same EU legal space. Neither model is fully coherent; they're political settlements as much as legal ones.

Where Poland sits relative to its neighbours

Germany completed its own significant cannabis law reform in 2024. The Czech Republic has a more permissive personal possession framework. Poland's trajectory has been more conservative, though the 2017 medical access reform was a meaningful step and there have been ongoing parliamentary debates about further liberalisation. Those debates have not yet produced enacted legislation beyond the medical framework.

From a comparative regulatory standpoint, Poland's structure, criminal prohibition for non-medical use, physician-prescription medical pathway, no formal decriminalisation threshold written into statute, is not unusual globally. What is unusual is the combination of EU novel food rules for CBD, strong pharmaceutical-grade requirements for medical products, and a prosecutorial-discretion approach to minor possession, all operating at the same time.

A note for Australian readers

If you are in Australia and interested in how cannabis access works here, the comparison with international frameworks can be useful context. In Australia, medicinal cannabis products are regulated by the TGA. THC-containing preparations are Schedule 8 controlled drugs; most CBD-only preparations above certain thresholds are Schedule 4 prescription only. Access occurs via the Special Access Scheme (SAS-B), the Authorised Prescriber scheme, or through products listed on the ARTG. None of the Polish law described here creates any right or pathway under Australian law.

The endocannabinoid system background that underpins research interest in cannabinoids globally is the same biology regardless of jurisdiction; but the regulatory wrapper around it differs enormously from country to country. Poland is one data point in a genuinely complex international picture.

Sources

• Poland Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Guidance on the use of medicinal cannabis in Australia, Therapeutic Goods Administration (TGA)
• Cannabis policy: status and recent developments; EMCDDA
• Medical Cannabis Policies in Europe, NCBI / PubMed Central

, Marcus Hale, Regulatory researcher, TGA & access law